FY2025 EPS Estimate for Kura Oncology Lowered by Analyst

Kura Oncology, Inc. (NASDAQ:KURA - Free Report) - Equities research analysts at Brookline Capital Management lowered their FY2025 earnings per share (EPS) estimates for shares of Kura Oncology in a research note issued to investors on Wednesday, February 26th. Brookline Capital Management analyst L. Cann now anticipates that the company will post earnings per share of ($2.01) for the year, down from their prior forecast of ($1.74). The consensus estimate for Kura Oncology's current full-year earnings is ($2.44) per share.

Several other equities analysts have also commented on KURA. BTIG Research lowered Kura Oncology from a "buy" rating to a "neutral" rating in a report on Thursday, February 6th. StockNews.com upgraded Kura Oncology from a "sell" rating to a "hold" rating in a report on Thursday, February 27th. HC Wainwright restated a "buy" rating and set a $40.00 target price on shares of Kura Oncology in a research note on Thursday, February 27th. JMP Securities reiterated a "market outperform" rating and issued a $28.00 price target on shares of Kura Oncology in a research note on Thursday, February 6th. Finally, TD Cowen reissued a "buy" rating on shares of Kura Oncology in a report on Thursday, November 21st. Four investment analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $25.50.

Remove Ads

Kura Oncology Stock Up 4.5 %

Shares of KURA traded up $0.33 during midday trading on Monday, reaching $7.70. The stock had a trading volume of 1,438,284 shares, compared to its average volume of 1,598,446. The company has a market cap of $598.78 million, a price-to-earnings ratio of -3.26 and a beta of 0.85. The company's fifty day simple moving average is $8.04 and its two-hundred day simple moving average is $13.51. Kura Oncology has a 1-year low of $6.98 and a 1-year high of $24.17. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.43. The firm had revenue of $53.88 million during the quarter, compared to analyst estimates of $57.96 million.

Insiders Place Their Bets

In other Kura Oncology news, insider Mollie Leoni sold 4,963 shares of the stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the sale, the insider now directly owns 88,253 shares of the company's stock, valued at approximately $694,551.11. This trade represents a 5.32 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Thomas James Doyle sold 4,949 shares of the business's stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the transaction, the senior vice president now directly owns 88,193 shares in the company, valued at approximately $694,078.91. The trade was a 5.31 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 11,729 shares of company stock valued at $92,307. Insiders own 5.50% of the company's stock.

Institutional Trading of Kura Oncology

Hedge funds have recently made changes to their positions in the company. Harbor Capital Advisors Inc. raised its holdings in Kura Oncology by 21.9% during the third quarter. Harbor Capital Advisors Inc. now owns 47,295 shares of the company's stock worth $924,000 after purchasing an additional 8,505 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in Kura Oncology by 35.2% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 29,655 shares of the company's stock worth $579,000 after purchasing an additional 7,722 shares during the period. Intech Investment Management LLC purchased a new position in shares of Kura Oncology during the 3rd quarter worth approximately $298,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Kura Oncology by 2.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 624,952 shares of the company's stock valued at $12,212,000 after buying an additional 14,106 shares during the period. Finally, Algert Global LLC boosted its stake in shares of Kura Oncology by 4.4% in the third quarter. Algert Global LLC now owns 272,276 shares of the company's stock valued at $5,320,000 after buying an additional 11,493 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.